skip to Main Content

Our Mission

A new era of modern medicine is emerging to combat the deadliest diseases that remain uncured, including cancer and autoimmune disorders. We believe understanding the complex interactions between molecules and cells will provide the key to the next generation of breakthrough therapies.

Recent discoveries have provided insights into how we can better utilize the immune system the way nature intended, and new advances in bioengineering have provided ways to leverage the immune system to our advantage. The world of treatment possibilities abounds with this knowledge and we are positioned to translate these findings into new medicines to better the human condition.

Our People

Ian Chan, MBA

Previously US Genomics, Morgan Stanley, Bear Stearns.
Education: AB Brown University, MBA Harvard University.

Eugene Chan, M.D.

Previously US Genomics.
Education: AB Harvard University, MD Harvard University.

Robert Markelewicz, Jr, MD, MMSc

Previously Celgene, Acetylon, Parexel.
Education: ScB Brown University, MMSc Brown University, MD Brown University.

Scientific Advisory Board

Bob Langer, Ph.D.

Institute Professor at MIT with over 840 written articles and over 500 issued or pending patents. Founder of AIR, Momenta, Acusphere, Tempo Pharma, others.

Laurie Glimcher, M.D.

President and CEO of Dana-Farber Cancer Institute; Professor, Harvard Medical School

Rita Colwell, Ph.D.

Chairman, Canon Life Sciences; Former Director NSF, appointed by Bill Clinton.

Ronald Levy, M.D.

Professor of Medicine, Director of the Lymphoma Program, Former Chief of the Division of Oncology at Stanford University.

Shiv Pillai, M.D, Ph.D.

Professor of Medicine, Harvard Medical School

Nai-Kong Cheung, M.D, Ph.D.

Head, Neuroblastoma Program; Enid A. Haupt Chair in Pediatric Oncology

George C. Tsokos, M.D.

Professor of Medicine, Harvard Medical School. Chief, Rheumatology Division.

Board of Directors

Ian Chan, MBA


Eugene Chan, M.D.


Bob Langer, Ph.D.
Miles Suk

Our Collaborators

Back To Top